Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 7 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 1810.88 | 245 / 245 | 99% | 69.88 | 497 / 502 |
thymus | 100% | 1408.59 | 652 / 653 | 99% | 55.81 | 596 / 605 |
intestine | 100% | 1684.46 | 966 / 966 | 98% | 67.56 | 517 / 527 |
lung | 100% | 1688.72 | 578 / 578 | 98% | 69.23 | 1128 / 1155 |
stomach | 100% | 1131.75 | 359 / 359 | 98% | 58.89 | 279 / 286 |
liver | 100% | 963.77 | 225 / 226 | 98% | 70.87 | 396 / 406 |
breast | 100% | 1546.36 | 459 / 459 | 96% | 83.61 | 1076 / 1118 |
skin | 99% | 794.46 | 1790 / 1809 | 96% | 106.51 | 455 / 472 |
uterus | 100% | 1265.28 | 170 / 170 | 95% | 91.72 | 437 / 459 |
bladder | 100% | 1244.90 | 21 / 21 | 95% | 82.27 | 479 / 504 |
kidney | 100% | 1700.02 | 89 / 89 | 95% | 62.69 | 856 / 901 |
ovary | 100% | 1452.18 | 180 / 180 | 92% | 53.74 | 397 / 430 |
esophagus | 98% | 1042.12 | 1414 / 1445 | 93% | 46.52 | 171 / 183 |
pancreas | 91% | 474.34 | 299 / 328 | 99% | 88.24 | 176 / 178 |
adrenal gland | 100% | 2398.58 | 258 / 258 | 84% | 33.45 | 193 / 230 |
brain | 85% | 482.34 | 2250 / 2642 | 96% | 55.56 | 679 / 705 |
adipose | 100% | 1590.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 144.06 | 29 / 29 |
spleen | 100% | 2513.60 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 105.70 | 45 / 45 |
heart | 99% | 759.37 | 854 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 971.04 | 1321 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2365.00 | 919 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 63.61 | 79 / 80 |
muscle | 45% | 149.92 | 362 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002281 | Biological process | macrophage activation involved in immune response |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0034145 | Biological process | positive regulation of toll-like receptor 4 signaling pathway |
GO_0045089 | Biological process | positive regulation of innate immune response |
GO_1901223 | Biological process | negative regulation of non-canonical NF-kappaB signal transduction |
GO_0045087 | Biological process | innate immune response |
GO_0005730 | Cellular component | nucleolus |
GO_0005615 | Cellular component | extracellular space |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0016020 | Cellular component | membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IFI35 |
Protein name | Interferon-induced 35 kDa protein (IFP 35) (Ifi-35) |
Synonyms | IFP35 |
Description | FUNCTION: Acts as a signaling pathway regulator involved in innate immune system response . In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation . In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production . In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries . Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion . Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines . . |
Accessions | ENST00000415816.7 [P80217-1] P80217 ENST00000438323.2 [P80217-2] |